Skip to content
Search

Latest Stories

'Omicron less likely to cause long Covid'

The Omicron variant of coronavirus is less likely to cause long Covid than previous variants, according to the first peer-reviewed study of its kind from the UK.

Researchers at King's College London, using data from nearly 100,000 people who logged their Covid symptoms via an app, found the odds of developing long Covid after infection were 20 per cent to 50 per cent lower during the Omicron wave in the UK compared to Delta. The figure varied depending on the patient's age and the timing of their last vaccination.


Long Covid, which includes prolonged symptoms ranging from fatigue to 'brain fog', can be debilitating and continue for weeks or months. It is increasingly being recognised as a public health problem, and researchers have been racing to find out if Omicron presents as big a risk of long Covid as previously dominant variants.

The study from King's is believed to be the first academic research to show Omicron does not present as great a risk of long Covid, but that does not mean long Covid patient numbers are dropping, the team said.

While the risk of long Covid was lower during Omicron, more people were infected, so the absolute number now suffering is higher.

"It's good news, but please don't decommission any of your long Covid services," lead researcher Dr Claire Steves said, appealing to health-service providers.

The UK's Office for National Statistics said in May that 438,000 people in the country have long Covid after Omicron infection, representing 24 per cent of all long Covid patients.

It also said the risk of lingering symptoms after Omicron was lower than with Delta, but only for double-vaccinated people. It found no statistical difference for those who were triple vaccinated.

In the King's research, 4.5 per cent of the 56,003 people studied during Omicron's peak, December 2021-March 2022, reported long Covid. That compared to 10.8 Covid of 41,361 people during the Delta wave, June-November 2021. It did not compare vaccinated and unvaccinated individuals.

While the study – published in The Lancet last week – compared Delta and Omicron, Dr Steves said previous work had showed no substantial difference in long Covid risk between other variants.

More work was needed to establish why Omicron may have a lower long Covid risk, the team added.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less